Fucose
Names | |
---|---|
IUPAC name (3S,4R,5R,6S)-6-Methyltetrahydro-2H-pyran-2,3,4,5-tetraol | |
Other names 6-Deoxy-L-galactose | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
ECHA InfoCard | 100.017.684 |
PubChem CID |
|
UNII |
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C6H12O5 |
Molar mass | 164.16 |
Supplementary data page | |
Structure and properties | Refractive index (n), Dielectric constant (εr), etc. |
Thermodynamic data | Phase behaviour solid–liquid–gas |
Spectral data | UV, IR, NMR, MS |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Y verify (what is YN ?) | |
Infobox references | |
Fucose is a hexose deoxy sugar with the chemical formula C6H12O5. It is found on N-linked glycans on the mammalian, insect and plant cell surface. Fucose is the fundamental sub-unit of the seaweed polysaccharide fucoidan.[1]α(1→3) linked core fucose is a suspected carbohydrate antigen for IgE-mediated allergy.[2]
Two structural features distinguish fucose from other six-carbon sugars present in mammals: the lack of a hydroxyl group on the carbon at the 6-position (C-6) (thereby making it a deoxy sugar) and the L-configuration. It is equivalent to 6-deoxy-L-galactose.
In the fucose-containing glycan structures, fucosylated glycans, fucose can exist as a terminal modification or serve as an attachment point for adding other sugars.[3]
In human N-linked glycans, fucose is most commonly linked α-1,6 to the reducing terminal β-N-acetylglucosamine. However, fucose at the non-reducing termini linked α-1,2 to galactose forms the H antigen, the substructure of the A and B blood group antigens.
Fucose is released from fucose-containing polymers by an enzyme called α-fucosidase.
L-Fucose is claimed to have application in cosmetics, pharmaceuticals, and dietary supplements. However, these claims are often not supported by peer-reviewed scientific studies.
Fucosylation of antibodies has been established to reduce binding to the Fc receptor of Natural Killer cells and thereby reduce antigen-dependent cellular cytotoxicity. Therefore afucosylated monoclonal antibodies have been designed to recruit the immune system to cancers cells have been manufactured in cell lines deficient in the enzyme for core fucosylation (FUT8) and thereby enhancing the in vivo cell killing.[4][5]
See also
Digitalose, the methyl ether of D-fucose- Fucitol
- Verotoxin-producing Escherichia coli
References
^ "Polysaccharides from macroalgae: Recent advances, innovative technologies and challenges in extraction and purification". Food Research International. 99: 1011–1020. 2017-09-01. doi:10.1016/j.foodres.2016.11.016. ISSN 0963-9969..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}
^ Daniel J. Becker; John B. Lowe (July 2003). "Fucose: biosynthesis and biological function in mammals". Glycobiology. 13 (7): 41R–53R. doi:10.1093/glycob/cwg054. PMID 12651883.
^ Daniel J. Moloney; Robert S. Haltiwanger (July 1999). "The O-linked fucose glycosylation pathway: identification and characterization of a uridine diphosphoglucose: fucose-[beta]1,3-glucosyltransferase activity from Chinese hamster ovary cells". Glycobiology. 9 (7): 679–687. doi:10.1093/glycob/9.7.679. PMID 10362837.
^ Dalziel, Martin; Crispin, Max; Scanlan, Christopher N.; Zitzmann, Nicole; Dwek, Raymond A. (2014-01-03). "Emerging Principles for the Therapeutic Exploitation of Glycosylation". Science. 343 (6166): 1235681. doi:10.1126/science.1235681. ISSN 0036-8075. PMID 24385630.
^ Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering". BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278.